Mumbai : A strategic collaboration has been worked out in between Dr. Reddy’s Laboratories and TR-Pharm to manufacture and commercialize a portfolio of biosimilar drugs in Turkey.
According to this agreement , a total of three products have been registered as subsequently commercialized, by TR-Pharm in Turkey. On completion of its facility investment TR-Pharm will be manufacturing the drug substance and drug product in it.
According to IFFL, Dr Reddys Laboratories Ltd is currently trading at Rs. 3202, up by Rs. 17.75 or 0.56% from its previous closing of Rs. 3184.25 on the BSE.
The scrip opened at Rs. 3175 and has touched a high and low of Rs. 3223.35 and Rs. 3175 respectively. So far 145749 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 54325.74 crore.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750 on 21-Jan-2016. Last one week high and low of the scrip stood at Rs. 3280 and Rs. 3163.5 respectively.
The promoters holding in the company stood at 25.57 % while Institutions and Non-Institutions held 43.5 % and 30.93 % respectively.
The stock is currently trading below its 200 DMA.